866-997-4948(US-Canada Toll Free)

Injectable Drug Delivery Partnering 2009-2014

Published By :

Current Partnering

Published Date : Aug 2014

Category :

Drug Delivery

No. of Pages : 150 Pages


Injectable Drug Delivery Partnering 2009-2014 report provides understanding and access to the injectable drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.
 
  • Trends in injectable drug delivery partnering deals
  • Top injectable drug delivery deals by value
  • Deals listed by company A-Z, deal type, stage of development, therapy type
 
Injectable Drug Delivery Partnering 2009-2014 provides understanding and access to the injectable drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter injectable drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors injectable drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
 
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
                                
This report contains over 180 links to online copies of actual injectable drug delivery deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal. 
 
The initial chapters of this report provide an orientation of injectable drug delivery dealmaking and business activities. 

Chapter 1 provides an introduction to the report, whilst 

Chapter 2 provides an overview of the trends in injectable drug delivery dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.Chapter 2 also contains case studies providing an insight into how companies enter into injectable drug delivery dealmaking.
                    
Chapter 3 provides a review of the leading injectable drug delivery deals since 2009. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
 
Chapter 4 provides a comprehensive directory of injectable drug delivery partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and therapy type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
  
The report also includes numerous tables and figures that illustrate the trends and activities in injectable drug delivery partnering and dealmaking since 2009.
 
In conclusion, this report provides everything a prospective dealmaker needs to know about injectable drug delivery partnering in the research, development and commercialization of drug delivery technologies and products.
 
Report scope
 
Injectable Drug Delivery Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to injectable drug delivery trends and structure of deals entered into by leading companies worldwide.
 
This data driven report includes:
 
  • Trends in injectable drug delivery dealmaking in the biopharma industry since 2009
  • Access to summary headline, upfront, milestone and royalty data
  • Access to over 180 injectable drug delivery contract documents
  • The leading injectable drug delivery deals by value since 2009
 
In Injectable Drug Delivery Partnering 2009-2014, the available deals are listed by:
 
  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Company A-Z
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Therapy type
 
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Injectable Drug Delivery Partnering 2009-2014 provides the reader with the following key benefits:
 
  • In-depth understanding of injectable drug delivery deal trends since 2009
  • Access to summary headline, upfront, milestone and royalty data
  • Comprehensive access to over 180 actual deal records entered into by the world’s biopharma companies since 2009
  • Insight into key deal terms included in contracts, where disclosed
  • Understand the key deal terms companies have agreed in deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Table of Content

Executive Summary
 
Chapter 1 – Introduction
 
Chapter 2 – Trends in injectable drug delivery partnering
2.1. Introduction
2.2. Injectable drug delivery partnering over the years
2.3. Big pharma injectable drug delivery dealmaking activity
2.4. Big biotech injectable drug delivery dealmaking activity
2.5. Injectable drug delivery partnering by deal type
2.6. Injectable drug delivery partnering industry sector
2.7. Injectable drug delivery partnering by stage of development
2.8. Injectable drug delivery partnering by therapy type
2.9. Disclosed financial deal terms for injectable drug delivery partnering
2.9.1 Injectable drug delivery headline values
2.9.2 Injectable drug delivery upfront payments
2.9.3 Injectable drug delivery milestone payments
2.9.4 Injectable drug delivery royalty rates
 
Chapter 3 – Leading injectable drug delivery deals
3.1. Introduction
3.2. Top injectable drug delivery deals by value
 
Chapter 4 – Injectable drug delivery dealmaking directory
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By therapy type
Hospital care
Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Gynecology
Hematology
Hospital care
Immunology
Infectious diseases
Metabolic & endocrinology
Musculoskeletal
Obstetrics
Orphan Diseases
Oncology
Ophthalmology
Pediatrics
Psychiatry
Public health
Rehabilitation medicine
Respiratory
Sensory organ
Sexual health
 
Chapter 5 – Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

List of Chart

 
Figure 1: Injectable drug delivery partnering since 2009
Figure 2: Big pharma – top 50 – Injectable drug delivery deals 2009 to 2014
Figure 3: Big biotech– top 50 – Injectable drug delivery deals 2009 to 2014
Figure 4: Big pharma injectable drug delivery deal frequency – 2009 to 2014
Figure 5: Big biotech injectable deal frequency – 2009 to 2014
Figure 6: Injectable drug delivery partnering by deal type since 2009
Figure 7: Injectable drug delivery partnering by industry sector since 2009
Figure 8: Injectable drug delivery partnering by stage of development since 2009
Figure 9: Injectable drug delivery partnering by therapy type since 2009
Figure 10: Injectable drug delivery deals with a headline value
Figure 11: Injectable drug delivery deals with upfront payment values
Figure 12: Injectable drug delivery deals with milestone payments
Figure 13: Injectable drug delivery deals with royalty rates, %
Figure 14: Top Injectable drug delivery deals by value since 2009
Figure 15: Online partnering resources
Figure 16: Forthcoming partnering events
Figure 17: Deal type definitions

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *